Earnings summaries and quarterly performance for ANAPTYSBIO.
Executive leadership at ANAPTYSBIO.
Board of directors at ANAPTYSBIO.
Research analysts covering ANAPTYSBIO.
Recent press releases and 8-K filings for ANAB.
AnaptysBio Details Strategic Separation and Pipeline Progress
ANAB
New Projects/Investments
Legal Proceedings
Guidance Update
- AnaptysBio plans a strategic separation into two independent businesses in 2026: a royalty management business and a biopharma assets business.
- The biopharma segment will focus on ANB033, with celiac disease trial data expected in Q4 2026, and Rosnilimab, which will advance to Phase 3 development for rheumatoid arthritis in 2026 with external funding.
- The royalty business is anchored by Jemperli, projected to achieve $1.4 billion in sales for GSK in 2025, contributing approximately $100 million in royalty income to AnaptysBio in 2025.
- The company expects to end 2025 with $300 million in cash, including a $75 million milestone from GSK, and anticipates paying off its non-recourse debt by Q2 2027.
- AnaptysBio is involved in litigation with GSK regarding Jemperli, with an expedited trial expected by summer 2026.
Dec 3, 2025, 12:55 PM
AnaptysBio Details Planned Business Separation and Pipeline Progress
ANAB
M&A
New Projects/Investments
Legal Proceedings
- AnaptysBio plans to separate its business into two independent entities in 2026: a biopharma operations company and a royalty management company.
- The biopharma company's lead asset, ANB033, a CD122 antagonist, initiated a trial in celiac disease in 2025 with data expected in Q4 2026, and a second trial in EOE will start in 2026.
- Rosnilimab, for rheumatoid arthritis, showed positive Phase 2b data and is slated for Phase 3 development in 2026, contingent on external funding. An end-to-phase 2 meeting with the FDA is scheduled by the end of Q1 2026.
- The royalty business includes rights to Jemperli, which is projected to reach $1.4 billion in sales by the end of 2025. AnaptysBio is engaged in litigation with GSK regarding Jemperli, with an expedited trial anticipated by summer 2026.
- AnaptysBio expects to end 2025 with $300 million in cash, including an accrued $75 million milestone from GSK. The royalty management business is projected to be cash flow positive by Q2 2027 after debt repayment.
Dec 3, 2025, 12:55 PM
AnaptysBio Outlines Biopharma Split and Drug Development Timelines
ANAB
New Projects/Investments
Legal Proceedings
Guidance Update
- AnaptysBio plans to split its operations into two independent publicly traded companies by year-end 2026, comprising a royalty management business and a biopharma business, with the separation potentially occurring in the first half of the year.
- The company anticipates ending the current year with $300 million in cash, including an accrued $75 million payment from a Jemperli milestone, and is committed to separating the biopharma business with at least two years of capital.
- For its rosnilimab program for Rheumatoid Arthritis, AnaptysBio is preparing Phase 3 trial designs for an FDA meeting by the end of Q1 and will provide an update on its advancement and financing strategy in the first half of next year.
- The AMB-033 celiac disease trial is expected to read out the totality of its Phase 1b study data in Q4 of next year.
Dec 2, 2025, 6:30 PM
AnaptysBio Announces Biopharma Operational Split and Program Updates
ANAB
New Projects/Investments
Guidance Update
- AnaptysBio plans an operational split of its biopharma and royalty management businesses, targeting completion by year-end 2026. This will create two independent publicly traded companies, with the current AnaptysBio becoming the royalty business and the biopharma assets spinning off.
- The company anticipates ending 2025 with $300 million in cash, which includes a $75 million Jemperli milestone payment. The separated biopharma business will be capitalized with at least two years of operating capital.
- For AMB-033 in celiac disease, phase 1b study results are expected in Q4 2026.
- For rosnilimab in rheumatoid arthritis, an FDA end-of-phase 2 meeting is planned by the end of Q1 2026, with an update on phase 3 advancement expected in the first half of 2026.
Dec 2, 2025, 6:30 PM
AnaptysBio Announces Biopharma Operational Split and Provides Clinical Program Updates
ANAB
New Projects/Investments
Guidance Update
- AnaptysBio plans to split its operations into two independent publicly traded companies by year-end 2026, potentially in the first half of 2026, separating its royalty management business from its biopharma assets.
- The biopharma business is projected to end 2025 with $300 million in cash, including a $75 million payment from GSK, and will be separated with at least two years of capital.
- Top-line data for the Phase I-B study of AMB-033 in celiac disease is expected in Q4 of next year (2026).
- AnaptysBio will meet with the FDA by the end of Q1 (2026) for an end-of-Phase II meeting for rosnilimab in rheumatoid arthritis and will provide an update on its advancement in the first half of next year (2026).
Dec 2, 2025, 6:30 PM
AnaptysBio Files Lawsuit Against Tesaro and GSK Over Collaboration Agreement
ANAB
Legal Proceedings
- AnaptysBio, Inc. initiated a lawsuit on November 20, 2025, in Delaware Chancery Court, alleging that Tesaro, Inc. materially breached their Collaboration and Exclusive License Agreement and that GlaxoSmithKline (GSK) tortiously interfered with the agreement.
- The complaint states that Tesaro and GSK allegedly withheld material information, including an ongoing I-SPY Trial involving dostarlimab, and prioritized GSK's antibody-drug conjugate (ADC) programs over optimizing dostarlimab's commercial opportunity.
- AnaptysBio is seeking a court declaration that Tesaro's breaches are incurable, which would entitle AnaptysBio to all rights and remedies under the agreement, including the reversion of rights to dostarlimab.
- In response, Tesaro and GSK publicly filed their own complaint against AnaptysBio on November 26, 2025, claiming AnaptysBio breached the Collaboration Agreement.
Nov 26, 2025, 9:00 PM
ANAPTYSBIO announces $100 million stock repurchase plan
ANAB
Share Buyback
- AnaptysBio, Inc. announced an amended Stock Repurchase Plan, authorizing the repurchase of up to an additional $100.0 million of its common stock.
- This new authorization is in addition to the $6.4 million that remained as of November 20, 2025, under the previous $75.0 million Stock Repurchase Plan.
- Under the prior plan, Anaptys had repurchased a total of 3,443,188 shares of common stock, representing 11.2% of shares outstanding before the start of that plan.
- The Stock Repurchase Plan is scheduled to expire on March 31, 2026.
- Anaptys anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, including an expected $75 million commercial sales milestone in Q4 2025 from GSK.
Nov 21, 2025, 2:01 PM
AnaptysBio Announces Business Separation and Clinical Program Updates
ANAB
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- AnaptysBio plans to separate its business into two entities: biopharma operations and a royalty management business, with the separation possibly occurring by the first half of 2026.
- The company expects to exit 2025 with $300 million of cash.
- The royalty management business is driven by Jemperli (GSK), which is anticipated to be on a $1.4 billion-$1.5 billion run rate exiting 2025 and has royalty tiers ranging from 8% to 25%. GSK's guidance suggests peak sales could convert to $390 million a year for AnaptysBio.
- Key clinical program updates include Rosnilimab, which had a positive Phase 2b readout in arthritis and is being assessed for Phase 3 trials in 2026 , and AMV033, with Phase 1b celiac disease trial results anticipated in Q4 2026.
Nov 17, 2025, 4:00 PM
AnaptysBio Announces Business Separation and Pipeline Updates
ANAB
New Projects/Investments
Revenue Acceleration/Inflection
- AnaptysBio plans to separate its business into two entities in 2026, creating a biopharma operations business and a royalty management business.
- The company is well-capitalized with an expected $300 million of cash coming out of this year.
- The royalty management business includes significant streams from Jemperli, which is anticipated to be on a $1.4 billion-$1.5 billion run rate exiting this year, with royalty tiers up to 25%. A non-recourse debt obligation related to these royalties is expected to be paid down by Q2 2027.
- In its biopharma operations, Rosnilimab is being assessed for advancement into Phase 3 trials for rheumatoid arthritis following positive Phase 2b data.
- AMV033 is in a Phase 1b trial for celiac disease, with results anticipated in Q4 2026, and a second Phase 1b indication will launch in 2026.
Nov 17, 2025, 4:00 PM
AnaptysBio Announces Business Separation and Clinical Pipeline Updates
ANAB
New Projects/Investments
Revenue Acceleration/Inflection
Product Launch
- AnaptysBio plans to separate its business into two (biopharma and royalty management) with the separation potentially occurring by the first half of 2026.
- The company anticipates exiting 2025 with $300 million in cash.
- Its royalty management business includes Jemperli, projected to have a $1.4 billion-$1.5 billion run rate exiting 2025, and imsidolimab, with anticipated approval next year.
- Key clinical programs include Rosnilimab (positive Phase 2b in arthritis, Phase 3 advancement in 2027) and AMV033 (Phase 1b for celiac disease, results expected Q4 2026).
Nov 17, 2025, 4:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more